Collaboration aims to enhance early detection
of esophageal cancer in at-risk patients through strategic
co-marketing initiatives serving firefighters
NEW YORK,
Sept. 3,
2024 /PRNewswire/ -- Lucid Diagnostics
Inc. (Nasdaq: LUCD) ("Lucid" or the "Company")
a commercial-stage, cancer prevention medical diagnostics company
and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the
execution of a memorandum of understanding (MOU) with Front Line
Mobile Health ("Front Line"), a comprehensive medical care
provider for first responders. The MOU focuses on the exploration
of co-marketing and collaboration opportunities to promote and
expand patient access to Lucid's EsoGuard® Esophageal
DNA test for the early detection of esophageal precancer,
particularly among firefighters. Lucid previously collaborated with
Front Line to facilitate its first major directly-contracted
#CheckYourFoodTube Precancer Testing Event.
"Lucid Diagnostics is committed to widespread
early detection of esophageal precancer," said Shaun O'Neil, Lucid's President and Chief
Operating Officer. "We are honored to have provided EsoGuard
precancer testing to thousands of firefighters across the
nation. Every day they risk their lives to protect us, and Lucid is
committed to protecting them in return. This partnership allows us
to expand these efforts by leveraging Front Line's resources and
extensive expertise caring for firefighters. We are excited to
further collaborate with Front Line to increase access to
esophageal precancer testing for firefighters and drive revenue
through contracted high-volume testing events."
"At Front Line Mobile Health, we are deeply
committed to protecting the health and safety of our nation's
firefighters, who face a 62% higher risk of developing esophageal
cancer," said Russell A. Burnham,
APA-C, Front Line's Team Principal and Chief Executive Officer.
"Lucid's EsoGuard Esophageal DNA Test is a powerful tool in this
endeavor, offering early detection of esophageal precancer and
thereby safeguarding the well-being of these brave individuals. We
look forward to expanding our partnership with Lucid and leveraging
our strong relationships with fire departments to broaden access to
this potentially life-saving tool."
Front Line is a veteran-owned company that
specializes in providing comprehensive medical care for first
responders, including fire, law enforcement, and emergency medical
services. Front Line is a leading platform in public safety health
and wellness and is dedicated to focusing on physical, behavioral,
and operational health through patient education, disease
prevention, and operational optimization.
About Lucid Diagnostics
Lucid
Diagnostics Inc. is a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
Lucid is focused on the millions of patients with gastroesophageal
reflux disease (GERD), also known as chronic heartburn, who are at
risk of developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit
www.luciddx.com and for more information about its parent company
PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press
release includes forward-looking statements that involve risk and
uncertainties. Forward-looking statements are any statements that
are not historical facts. Such forward-looking statements, which
are based upon the current beliefs and expectations of Lucid's
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of Lucid's common
stock; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time
required to advance Lucid's products to regulatory submission;
whether regulatory authorities will be satisfied with the design of
and results from Lucid's clinical and preclinical studies; whether
and when Lucid's products are cleared by regulatory authorities;
market acceptance of Lucid's products once cleared and
commercialized; Lucid's ability to raise additional funding as
needed; and other competitive developments. In addition, Lucid
continues to monitor the COVID-19 pandemic and the pandemic's
impact on Lucid's businesses. These factors are difficult or
impossible to predict accurately and many of them are beyond
Lucid's control. In addition, new risks and uncertainties may arise
from time to time and are difficult to predict. For a further list
and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-signs-memorandum-of-understanding-with-front-line-mobile-health-302236348.html
SOURCE Lucid Diagnostics
